Indian Journal of Dermatology
THERAPEUTIC ROUND
Year
: 2012  |  Volume : 57  |  Issue : 2  |  Page : 118--122

Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis


Masoud Maleki1, Gholamreza Karimi2, Mohsen Tafaghodi3, Somayyeh Raftari3, Yalda Nahidi1,  
1 Research Center for Skin Diseases and Cutaneous Leishmanaisis, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Pharmacology and Toxicology, Medical Toxicology Research Center, Iran
3 Department of Pharmacology, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence Address:
Yalda Nahidi
Research Center for Skin Diseases and Cutaneous Leishmanaisis, Imam Reza Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad
Iran

Abstract

Introduction: Cutaneous leishmaniasis is an endemic disease in developing countries caused by different species of leishmania parasite, and if left untreated, it will result in a deformed scar after a relatively long period. Although various systemic and topical treatments have been proposed for leishmaniasis, pentavalent Antimony compounds remain the first-line treatment for it. Considering the cases with treatment failure, potential side effects and reluctance of patients to receive the drug, there are continuing efforts to find better treatment alternatives. Aim: Comparison of the effect of intralesional 2% zinc sulfate injection with Glucantime in treatment of acute cutaneous leishmaniasis. Materials and Methods: In this clinical trial, 45 patients with clinical diagnosis of cutaneous leishmaniasis and positive direct smear for leishman body were treated by intralesional injection of either 2% zinc sulfate or Glucantime. After simple randomization, in one group the patients were treated with 2 bouts of intralesional 2% zinc sulfate with a 2-week interval, and in the other group they were treated with 6 weekly bouts of intralesional Glucantime. The patients were monitored in two week intervals for 8 weeks. Healing of the lesions was evaluated clinically and by direct smear, and the data were analyzed using SPSS (11.5) software, t-Student, Mann-Whitney and Analysis of covariance (ANCOVA) statistical tests. Findings: In the end of study, 34 patients completed the study, 10 of whom received intralesional Glucantime and 24 of whom received intralesional 2% zinc sulfate. The healing rate after 8 weeks was 80% in the group receiving intralesional Glucantime and 33.3% in the one receiving 2% zinc sulfate (P=0.009). Conclusion: Based on the results of this study, intralesional injection of 2% zinc sulfate was less effective in treatment of cutaneous leishmaniasis than intralesional Glucantime.



How to cite this article:
Maleki M, Karimi G, Tafaghodi M, Raftari S, Nahidi Y. Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis.Indian J Dermatol 2012;57:118-122


How to cite this URL:
Maleki M, Karimi G, Tafaghodi M, Raftari S, Nahidi Y. Comparison of intralesional two percent zinc sulfate and glucantime injection in treatment of acute cutaneous leishmaniasis. Indian J Dermatol [serial online] 2012 [cited 2020 Apr 3 ];57:118-122
Available from: http://www.e-ijd.org/text.asp?2012/57/2/118/94279


Full Text

 Introduction



Cutaneous leishmaniasis is a skin disease caused by different species of leishmania with specific inclination of each species to a particular geographical region. It is endemic in 88 countries including Iran, Iraq, Brazil, Afghanistan, Peru, Sudan and Syria. It has afflicted 12 million people with 1-1.5 million new cases each year putting 350 million people at risk. It is becoming a global problem with increasing incidence due to immigration and travel. [1] Hyperendemicity of leishmaniasis in Iran has made it an important health problem in this country demanding high annual expenses. Although cutaneous leishmaniasis is a self-limiting disease, its healing takes months to years and in some cases it becomes chronic. On the other hand, healing is associated with a deformed scar. [2] Despite multiple treatment suggestions for cutaneous leishmaniasis, pentavalent Antimony compounds are used as first-line treatment, [3] but regarding their serious potential side effects including cardiac, hepatic and blood toxicity and pancreatitis, increased cases of clinical response failure, [4] high prices, lack of production technology in many of the developing endemic countries and prolonged treatment period, there are still efforts for finding an effective treatment with less side effects acceptable for patients. In numerous studies, oral zinc sulfate has been reported effective in treatment of cutaneous leishmaniasis. [5],[6],[7] Efficacy of intralesional zinc sulfate is debated in various studies, so that in Sharquie study it has been very effective [8] while in that of Firooz its efficacy has been reported to be inferior to intralesional Glucantime. [9] Therefore, we decided to compare the effect of intralesional zinc sulfate in treatment of acute cutaneous leishmaniasis with therapeutic effects of Glucantime in this clinical trial study.

 Materials and Methods



This randomized clinical trial was performed from March to September 2004 on patients with cutaneous leishmaniasis admitted to Imam Reza Hospital in Mashhad. Patients with clinical diagnosis of cutaneous leishmaniasis were included in the study according to the inclusion criteria after laboratory confirmation.

Inclusion criteria



Confirmation of cutaneous leishmaniasis based on direct smearNumber of lesions being less or equal to 3Duration of the disease being shorter than 12 weeksMinimum age being 7 and maximum 60 years oldCompletion of informed consent form by patient or parents of minor patientsDry cutaneous leishmaniasis

Exclusion criteria



Pregnant or breast feeding women, infants lower the age of 7Lesions on ear, nose, joints and near the eyeNumber of lesions more than 3Application of any kind of treatment for cutaneous leishmaniasisDuration of the disease longer than 12 weeks (to omit spontaneous healing cases during the follow-up period)Recurrent infectionWet cutaneous leishmaniasis

According to these criteria, 45 patients were studied in two groups of A (treated with intralesional zinc sulfate) and B (treated with intralesional Glucantime). Eleven patients were excluded from the study for various reasons including painful injections, [6] the emergence of new lesions, [1] the need for systemic therapy [2] or failure to complete treatment; [2] and finally, 34 patients (including 24 patients in group A and 10 patients in group B) completed the study.

In order to prepare 2% solution of zinc sulfate, 2 g of dry zinc sulfate was dissolved per 100 ml double distilled water to make the transparent solution with pH=5. In order to sterilize the solution, first the solution was poured in serology glass and put for 20 minutes in 120C autoclave. In the next stage, the solution was passed by syringe through 0.2 mm color filter under laminar hood and transferred to vials of which the cap was sealed by paraffin.

To ensure a sterile solution, several culture samples were taken from vials for aerobic and anerobic bacteria with negative results. The solution was injected using insulin syringe needles in adjacent intact skin of the lesions with 45 degree angle so that the lesions were indurated and white. The average volume of injected solution per lesion was 0.2-0.5 ml. In group A, in each lesion injection of zinc sulfate was performed twice within 2 weeks. In group B, Glucantime was weekly injected in the lesions for 6 weeks using insulin syringe. The patients were monitored every 2 weeks for 8 weeks, and each patient completed a questionnaire including age, gender, lesion location, erythema size and induration of the lesions data. Rehabilitated lesions were assessed using clinical examination and determination of the induration size and erythema in the lesions. All the lesions were ultimately subject to direct smear. In conclusion, after 8 weeks the treatment response was recorded using the system of Sharquie: [10]



Slight: Partial reduction of erythema and edema Mild: Reduction of lesion size up to 30%Moderate: Reduction of lesion size between 30% and 60%Marked: Reduction of lesion size more than 60% or negative smearTotal tolerance: Complete healing of the lesion with negative smear

Treatment response was calculated in each group, and then the analysis was performed using SPSS (11.5) software and t-Student, Mann-Whitney and ANCOVA statistical tests.

 Results



From 35 patients in group A (treated with 2% zinc sulfate), 24 patients, and out of 15 patients in group B (treated with Glucantime), 10 patients completed the study. The level of changes in erythema and induration of the lesions in days 14, 28, 42 and 56 after treatment is summarized in [Table 1] and [Table 2], respectively. The results indicate that reduction of erythema and induration of the lesions 42 days after starting the treatment was significantly higher in group treated with Glucantime than that treated with zinc sulfate.{Table 1}{Table 2}

Comparing the mean average size of lesions in the two groups under study with adjustment relative to their size before treatment is shown in [Table 3], indicating higher reduction of lesion size relative to that before the treatment in the group treated with Glucantime compared to group treated with intralesional zinc sulfate.{Table 3}

Complete cure rate in the group treated with intralesional Glucantime after 8 weeks was 80%, and it was 33.3% in the group treated with intralesional 2% zinc sulfate indicating significantly higher efficacy of Glucantime in treatment of cutaneous leishmaniasis lesions relative to intralesional zinc sulfate (P=0.009) [Table 4].{Table 4}

The side effects seen in both groups were pain after injection and hyperpigmentation. Burning after injection and necrosis of the lesions were seen in all case in zinc sulfate group, and inflammation and swelling in only three patients who received zinc sulfate.

Photos of 2 of our patients in zinc sulfate group one with good response and another one without improvement are shown in [Figure 1], [Figure 2], [Figure 3], [Figure 4] and [Figure 5].{Figure 1}{Figure 2}{Figure 3}{Figure 4}{Figure 5}

 Discussion



Pentavalent Antimony compounds (Glucantime and Pentostam) are currently used as first-line treatment of cutaneous leishmaniasis. Due to the side effects of these drugs, lack of cost effectiveness in economic terms, absence of production technology in many endemic developing countries and inadequate efficacy in some cases, the search for effective, risk free and inexpensive drugs is necessary. Considering the fact that Glucantime is the salt of the heavy metal Antimony and inhibits the amastigote growth by stopping glycolytic function and fatty acid oxidation, researchers have turned to consider other less toxic heavy metals such as zinc; and the hypothesis has been proposed that zinc may be effective against leishmania parasite. Zinc sulfate with concentration used in this study has the effect of immune-stimulation, [11] and the zinc ion has the ability of protein precipitation. [12] On the other hand, it has been shown that intralesional 2% zinc sulfate has a high capacity to inhibit leishmania amastigote, and possibly exerts this function through tissue damage and severe inflammatory changes. [13] Zinc also directly affects the enzymatic system of leishmania parasite. [14]

Zinc can boost Th1-mediated immune responses and help combat intracellular pathogens, and in this way it may be effective against leishmania. [15] Zinc is an intracellular signal molecule that plays an important role in improving the function of macrophages, dendrocytes and monocytes and cell -mediated immunity that are in turn effective in body defense against leishmania. [16],[17] Zinc is involved in the determination of structural properties of molecules concerned with connection and entry of leishmania into white blood cells. [18] Several studies have shown that the serum zinc level in patients with leishmaniasis has been lower compared to control group; [19],[20],[21] and following treatment with Antimony compounds the serum zinc level has increased. [22] Regarding the above statements, several clinical trials have been conducted to evaluate the effects of oral and intralesional zinc sulfate in the treatment of cutaneous leishmaniasis.

Najim et al showed that oral zinc sulfate is effective on leishmania parasite both extracorporally and in animal body. [5] Sharquie et al evaluated the effect of different doses of oral zinc sulfate in treatment of cutaneous leishmaniasis. Their results showed that the rate of healing in the group receiving oral zinc sulfate with 2.5 mg/kg/day dose for 31.8±18 days was 89.3%, in the group receiving 5 mg/kg/day dose for 29.9±1.7 days 93.1%, and in the group with 10 mg/kg/day dose for 28.3±1.4 days 96.6%. [6] Sharquie introduced in 2004 a case of disseminated cutaneous leishmaniasis treated with oral zinc sulfate with 10 mg/kg/day dose divided to three bouts for 4 months. [7]

In a clinical trial conducted by Sharquie et al in 1997, cutaneous Leishmaniasis patients were subject to treatment by intralesional zinc sulfate, Glucantime and 7% sodium chloride solution. Based on the results of this study, 33 out of 38 (84.8%) lesions treated with intralesional 2% zinc sulfate showed complete healing following a bout of intralesional injection, and 94.7% of lesions were completely healed by two times injection within 10-15 days. [8]

Iraji et al in 2005 conducted a study to compare the effect of 2% zinc sulfate and intralesional Glucantime in the treatment of cutaneous leishmaniasis. The rate of healing after 6 weeks in 35 patients receiving Glucantime (6 weekly injections) was 60%, and it was 83.3% in 31 patients receiving 2% zinc sulfate (2 injections with 2-week interval). After weeks 2 and 4 post-treatment, the efficacy of treatment with zinc sulfate was higher than Glucantime (P<0.01), but after 6 weeks no difference between the two groups was observed (P>0.05). They concluded that treatment with intralesional zinc sulfate can be the alternative treatment for intralesional Glucantime. [23] In contrast, in the study by Firooz et al in 2005 in the form of a randomized double-blind controlled clinical trial, 31 cutaneous leishmaniasis lesions were treated with intralesional Glucantime and 19 lesions were treated with 2% zinc sulfate weekly for 6 weeks. A week after the end of treatment, complete healing was seen in 19 lesions (61.3%) in the first group and in two cases (10.5%) in the second group (P<0.05). It was shown that a 6-week treatment period with 2% intralesional zinc sulfate is less efficient in treatment of Old World leishmaniasis than intralesional Glucantime. [9]

In our study, like that of Firooz et al but more significantly, the rate of healing 8 weeks after starting the treatment in the group treated with intralesional Glucantime was 80%, and was significantly higher than the 33.3% rate of healing in the group treated with intralesional 2% zinc sulfate (P=0.009).

In justifying the differences observed between our study and investigations of other researchers in which zinc sulfate has been indicated the efficient treatment of cutaneous Leishmaniasis, the following points can be cited:



Difference in leishmania species causing cutaneous leishmaniasis in Mashhad, Isfahan and Iraq, and as a result difference in sensitivity of leishmania parasites to zinc sulfate.Difference in the formulation of zinc sulfate. Difference in method and frequency of zinc sulfate injection.

Generally, we must say that intralesional Glucantime injection compared with zinc sulfate is more effective in the healing of acute cutaneous leishmaniasis lesions, and pentavalent Antimony compounds make the first-line treatment of acute cutaneous leishmaniasis. In conclusion, we suggest that similar studies be performed with higher sample number, changing injection frequencies and zinc sulfate concentration, determining Leishmania subtype and its sensitivity to zinc sulfate for more precise conclusions.

References

1Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004;27:305-18.
2Dowlati Y. Treatment of cutaneous leishmaniasis (Old World). Clin Dermatol 1996;14:513-7.
3Khatami A, Firooz A, Gorouhi F, Dowlati Y. Treatment of acute Old World cutaneous leishmaniasis: A systematic review of the randomized controlled trials. J Am Acad Dermatol 2007;57:335.e1-29.
4Lawn SD, Yardley V, Vega-Lopez F, Watson J, Lockwood DN. New World cutaneous leishmaniasis in returned travellers: Treatment failures using intravenous sodium stibogluconate. Trans R Soc Trop Med Hyg 2003;97:443-5.
5Najim RA, Sharquie KE, Farjou IB. Zinc sulphate in the treatment of cutaneous leishmaniasis: An in vitro and animal study. Mem Inst Oswaldo Cruz 1998;93:831-7.
6Sharquie KE, Najim RA, Farjou IB, Al-Timimi DJ. Oral zinc sulphate in the treatment of acute cutaneous leishmaniasis. Clin Exp Dermatol 2001;26:21-6.
7Sharquie KE, Najim RA. Disseminated cutaneous leishmaniasis. Saudi Med J 2004;25:951-4.
8Sharquie KE, Najim RA, Farjou IB. A comparative controlled trial of intralesionally-administered zinc sulphate, hypertonic sodium chloride and pentavalent antimony compound against acute cutaneous leishmaniasis. Clin Exp Dermatol 1997;22:169-73.
9Firooz A, Khatami A, Khamesipour A, Nassiri-Kashani M, Behnia F, Nilforoushzadeh M, et al. Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: A randomized, double-blind, controlled clinical trial. J Drugs Dermatol 2005;4:73-9.
10Sharquie KE, Al-Talib KK, Chu AC. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol 1988;119:53-7.
11Faris RM, Jarallah JS, Khoja TA, al-Yamani MJ. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol 1993;32:610-2.
12Brody I. Topical treatment of recurrent herpes simplex and post-herpetic erythema multiforme with low concentrations of zinc sulphate solution. Br J Dermatol 1981;104:191-4.
13Najim RA, Sharquie KE, Al-Zubaidy SA. Possible mechanisms of action of the compounds injected intralesionally in the treatment of cutaneous leishmaniasis, in addition to their direct effects on the parasites. Ann Trop Med Parasitol 2006;100:33-8.
14Sharquie KE, Al-Azzawi KE. Intralesional therapy of cutaneous leishmaniasis with 2% zinc sulphate solution. J Pan-Arab League. Dermatologists 1996;7:41-6.
15Wintergerst ES, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. Ann Nutr Metab 2007;51:301-23.
16Prasad AS. Impact of the discovery of human zinc deficiency on health. J Am Coll Nutr 2009;28:257-65.
17Prasad AS. Zinc: Role in immunity, oxidative stress and chronic inflammation. Curr Opin Clin Nutr Metab Care 2009;12:646-52.
18Puentes F, Guzmán F, Marín V, Alonso C, Patarroyo ME, Moreno A. Leishmania: Fine mapping of the Leishmanolysin molecule's conserved core domains involved in binding and internalization. Exp Parasitol 1999;93:7-22.
19Kocyigit A, Erel O, Gurel MS, Avci S, Aktepe N. Alterations of serum selenium, zinc, copper, and iron concentrations and some related antioxidant enzyme activities in patients with cutaneous leishmaniasis. Biol Trace Elem Res 1998;65:271-81.
20Kocyigit A, Gur S, Erel O, Gurel MS. Associations among plasma selenium, zinc, copper, and iron concentrations and immunoregulatory cytokine levels in patients with cutaneous leishmaniasis. Biol Trace Elem Res 2002;90:47-55.
21Pasa S, Kargin F, Bildik A, Seyrek K, Ozbel Y, Ozensoy S. Serum and hair levels of zinc and other elements in dogs with visceral leishmaniasis. Biol Trace Elem Res 2003;94:141-7.
22Kocyigit A, Erel O, Seyrek A, Gurel MS, Aktepe N, Avci S, et al. Effects of antimonial therapy on serum zinc, copper and iron concentrations in patients with cutaneous Leishmaniasis in Turkey. J Egypt Soc Parasitol 1998;28:133-42.
23Iraji F, Vali A, Asilian A, Shahtalebi MA, Momeni AZ. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology 2004;209:46-9.